Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aduro Biotech (NQ: ADRO )

14.60 USD UNCHANGED
Last Price Updated: 7:22 PM EDT, Oct 5, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aduro Biotech

< Previous 1 2 3 4 5 6 Next >
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
From GlobeNewswire News Releases
Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics
From GlobeNewswire News Releases
Chinook Therapeutics Announces $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease
Chinook Therapeutics, Inc., a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced... 
From Business Wire News Releases
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results
From GlobeNewswire News Releases
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy
From GlobeNewswire News Releases
Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress
From GlobeNewswire News Releases
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
From GlobeNewswire News Releases
Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress
From GlobeNewswire News Releases
Aduro Biotech Provides Business Update and Reports First Quarter 2020 Financial Results
From GlobeNewswire News Releases
Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
From GlobeNewswire News Releases
Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference
From GlobeNewswire News Releases
Aduro Biotech to Present at the 9th Annual SVB Leerink Global Healthcare Conference
From GlobeNewswire News Releases
Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer
From GlobeNewswire News Releases
Aduro Biotech Announces Corporate Restructuring
From GlobeNewswire News Releases
Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at th
From GlobeNewswire News Releases
Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results
From GlobeNewswire News Releases
Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
From GlobeNewswire News Releases
Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference
From GlobeNewswire News Releases
Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamo
From GlobeNewswire News Releases
Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference
From GlobeNewswire News Releases
Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results
From GlobeNewswire News Releases
Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Adva
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand... 
From GlobeNewswire News Releases
Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand... 
From GlobeNewswire News Releases
Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand... 
From GlobeNewswire News Releases
Aduro Biotech Reports First Quarter 2019 Financial Results
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand... 
From GlobeNewswire News Releases
Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways,... 
From GlobeNewswire News Releases
Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways,... 
From GlobeNewswire News Releases
Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways,... 
From GlobeNewswire News Releases
Analysis: Positioning to Benefit within Pepsico, Arista Networks, Titan International, Northern Dynasty Minerals, Aduro Biotech, and Corning — Research Highlights Growth, Revenue, and Consolidated Res
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Pepsico, Inc. (NASDAQ:PEP),... 
From GlobeNewswire News Releases
Aduro Biotech to Present at the H.C. Wainwright Global Life Sciences Conference
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the H.C. Wainwright Global Life Sciences... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.